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Novel long-chain compounds with 
both immunomodulatory and 
MenA inhibitory activities against 
Staphylococcus aureus and its 
biofilm
Seoung-ryoung Choi, Joel Frandsen & Prabagaran Narayanasamy
Menaquinone (MK) biosynthesis pathway is a potential target for evaluating antimicrobials in gram-
positive bacteria. Here, 1,4-dihydroxy-2-naphthoate prenyltransferase (MenA) was targeted to 
reduce methicillin-resistant Staphylococcus aureus (MRSA) growth. MenA inhibiting, long chain-based 
compounds were designed, synthesized and evaluated against MRSA and menaquinone utilizing 
bacteria in aerobic conditions. The results showed that these bacteria were susceptible to most of 
the compounds. Menaquinone (MK-4) supplementation rescued MRSA growth, suggesting these 
compounds inhibit MK biosynthesis. 3a and 7c exhibited promising inhibitory activities with MICs 
ranging 1–8 μg/mL against MRSA strains. The compounds did not facilitate small colony variant 
formation. These compounds also inhibited the biofilm growth by MRSA at high concentration. 
Compounds 3a, 6b and 7c displayed a promising extracellular bactericidal activity against MRSA at 
concentrations equal to and four-fold less than their respective MICs. We also observed cytokines 
released from THP-1 macrophages treated with compounds 3a, 6b and 7c and found decreases in 
TNF-α and IL-6 release and increase in IL-1β. These data provide evidence that MenA inhibitors act as 
TNF-α and IL-6 inhibitors, raising the potential for development and application of these compounds as 
potential immunomodulatory agents.
Lipid-soluble vitamin K was discovered in 19291 as an essential nutrient for anti-hemorrhage. Its structure and 
chemical nature were previously reported2. It is biosynthesized by many bacteria including Escherichia coli, 
Mycobacterium tuberculosis and Staphylococcus aureus. Vitamin K can be divided into natural and synthetic 
forms; Vitamin K1 (phylloquinone) and K2 (menaquinone, MK-4) are natural forms stored in the fat tissue and 
liver. Several homologues of vitamin K2 (MK-7 to MK-15) are produced by bacteria by changing the length of 
the isoprenoid chain. Synthetic forms of K3 (menaphthone or menadione), K4, and K5 are used as a nutritional 
supplement or fungal growth inhibitor. In humans, phylloquionone is supplemented from food while menaqui-
nones (MKs) are produced by conversion of phylloquinone by intestinal bacteria. Humans do not possess a MK 
biosynthesis pathway, and MK is not utilized in the electron transport chain. Because of this, enzymes involved 
in either function have recently received attention as potential drug targets to treat Gram-positive pathogens.
Ubiquinone and MK play important roles in the prokaryote electron transport chain by transferring electrons 
between membrane bound protein complexes3. In Gram-positive bacteria, MK biosynthesis is essential for sur-
vival because MK is the only electron carrier in both aerobic and anaerobic conditions. MKs are biosynthesized via 
two independent classical and futalosin pathways4,5. Both pathways utilize chorismate as substrate - derived from 
phosphoenolpyruvate and D-erythrose-4-phosphate by the shikimate pathway - but do not share other similari-
ties. As shown in Fig. 1, 1,4-dihydroxy-2-naphthoate (DHNA) is synthesized from chorismate by MenFDHCEB 
enzymes involved in the classical MK pathway. Prenylation by MenA followed by methylation by methyltransferse 
Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, 
Omaha, Nebraska 68198, USA. Correspondence and requests for materials should be addressed to P.N. (email: 
p.narayanasamy@unmc.edu)
received: 03 October 2016
Accepted: 30 November 2016
Published: 10 January 2017
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7:40077 | DOI: 10.1038/srep40077
(MenG) convert the 2-naphthoate to MK. The futalosin pathway uses MqnABCD enzymes to synthesize 
1,4-dihydroxy-6-naphthoate which is converted to MK via a series of reactions catalyzed by unknown enzymes.
Inhibitors of enzymes involved in MK biosynthesis demonstrate that targeting these enzymes may lead to 
therapeutics for treatments of infections by Gram-positive bacteria including Bacillus subtilis, M. tuberculosis, 
and S. aureus6,7. 4-oxo-4-phenylbutanoate analogues were developed as MenB inhibitors active against MRSA and 
both replicating and nonreplicating M. tuberculosis8,9. Mechanism-based inhibitors of an acyl-CoA synthetase 
(MenE) have been reported with low micromolar IC50 values10–12. Inhibitors of MenD13 and MenC14 were also 
discovered, validating the classical menaquinone pathway as a potential target for the development of antibacte-
rial drugs. Here, we report the synthesis and evaluation of potential MenA inhibiting antimicrobials and immu-
nomodulatory compounds.
Results and Discussion
A transmembrane protein 1,4-dihydroxy-2-naphthoate prenyltransferase (MenA) catalyzes formation of demeth-
ylmenaquinone (DMMK) via consecutive decarboxylation and prenylation of DHNA (Fig. 1). MenA is a promis-
ing target for Gram-positive bacteria, especially MRSA and drug-resistant M.tb. Benzophenone-based analogues 
were synthesized and identified as MenA inhibitors against MRSA and nonreplicating and replicating M.tb15–18. 
However, benzoquinone analogues are known to be toxic due to the presence of a benzophenone moiety15,19–21. 
Previously, we reported that MenA inhibitors possessing a simple, chemical structural backbone of 7-methoxy 
naphthalene are highly active against Gram-positive bacteria with low micromolar MIC and IC50 values (com-
pound 1 and 2 in Fig. 2)6. Here, we synthesized novel compounds to explore structure-activity relationships 
(compounds 3 to 7 in Fig. 2), determined effect on cytokine expression by macrophages and reduced MRSA 
growth and its biofilm.
Antimicrobial activity of naphthalene derivatives. MICs were determined against methicillin-resistant 
S. aureus strains and Gram-positive and negative bacteria. We previously reported that compound 1 and 2 
exhibited inhibition of both M.tb and MenA enzyme activity with IC50 values of 6 and 5 μ g/mL, respectively6. 
We synthesized long chain compounds with different functionalities to improve activity. Various active groups 
were introduced at the terminal part of carbon chain (tail group) to find a lead structure and evaluate its 
structure-activity relationship against MRSA. As expected, all the synthesized compounds showed no inhibi-
tion against Gram-negative P. aeruginosa, whereas most of the compounds inhibited growth of Gram-positive 
bacteria including seven MRSA strains, MSSA, EF and two species of Mycobacterium. Compounds 3a, 3b, 3c 
and 7c showed the most potent inhibitory activities against all Gram-positive bacteria with MIC values ranging 
from 0.5 to 16 μ g/mL (Table 1). These compounds share a phenylethylamine group that plays an important role 
in growth inhibition of Gram-positive bacteria. Although the compounds are very active, replacing the fluorine 
in 3a with other halogens did not significantly improve the MIC, and introduction of bicyclic or tricyclic ring 
Figure 1. Menaquinone biosynthesis pathways. Classical menaquinone and alternative futalosine 
pathways from chorismate. MqnA: futalosine synthase, MqnB: futalosine hydrolase, MqnC: dehypoxanthinyl 
futalosine cyclase, MqnD: 1,4-dihydroxy-6-naphthoate synthase. MenF: isochorismate synthase, MenC: 
o-succinylbenzoate synthase. MenD: 2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylate 
synthase. MenH: (1R, 6R)-6-hydroxy-2-succinylcyclohexa-2, 4-diene-1-carboxylate synthase.
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in the terminal end reduced the activity (3d-3f). Replacing the amine group with oxazolidinone also did not 
improve the activity (3g-3h) but the linezolid control was active. Similarly, the presence of fluorine in the pip-
eridine group did not increase inhibitory activity (3i). Introduction of oxygen in the carbon chain had no effect 
on inhibitory activity (4a and 4b), but substitution of 4-fluorophenylethylamine at the tail end (4c) maintained 
activity. Modification of the 7-methoxynaphthalene group by replacing the methoxy group with bromine did 
not improve inhibitory activity of 4-fluorophenylethylamine compounds (5a-c). However, bromine substituted 
naphthalene increased activity for piperidine tail end substitution (5d). Likewise, replacement of methoxy group 
with benzyloxy group did not affect growth inhibition for piperidine terminal end but significantly reduced the 
activity of 4-fluorophenylethylamine terminal end (6a-e). These data show that a bulkier substitution is needed 
at any one of the terminal groups. Interestingly, it was found that 7c was the most potent inhibitor against all 
tested Gram-positive bacteria showing MIC between 1–6 μ g/mL. Dual substitution of 4-fluorophenylethylamine 
increased the activity, but dual substitution of piperidine or allyl amine decreased the activity.
MRSA growth rescued by menaquinone (MK-4). Rescue experiments were performed via resazurin 
reduction assay to investigate the effect of menaquinone in the presence of various concentrations (0.5–64 μ g/mL) 
of inhibitor 3a or 3c against two MRSA strains USA 700 or 200, respectively. MIC of 3a was 4 μ g/mL against 
USA 700 and 3c was 2 μ g/mL against USA 200 (Table 1). As shown in Fig. 3 and Figure S1, MIC values for both 
inhibitors increased in a concentration-dependent manner by addition of MK-4. MICs of both inhibitors moved 
to 64 μ g/mL in the presence of 0.5 mg/mL MK-4. Similarly, when the media is supplemented with 0.05 mg/mL 
MK-4, MICs increased to 16 μ g/mL. Thus, the rescue experiments suggested that menaquinone biosynthesis is 
inhibited by 3a and 3c.
Colony morphology. A slow growing auxotrophic bacterial subpopulation resulting from mutations in met-
abolic genes has very distinctive phenotype compared to its parent wild-type strain. Gene mutations, caused by 
environmental factors including treatment of antibiotics, metabolic defects and genetic defects, lead to slow grow-
ing small colony variants (SCV) of bacteria that are related to electron transport defective strains and thymidylate 
biosynthesis22,23. Among the clinical bacteria forming SCV, Pseudomonas aeruginosa, Enterococcus faecalis24,25, 
and S. aureus SCV are a more prominent problem due to their association with intracellular persistence and 
linked chronic recurrent and antibiotic-resistant infections. Patients with cystic fibrosis, a genetic disorder caused 
by a mutation in CFTR gene, are especially in danger of higher probability of S. aureus SCV infection which can 
persist intracellularly in the host26. Development of inhibitors that do not induce SCV are urgent and important 
to treat S. aureus. We tested 3a, to analyze induction of SCV by growing MRSA on TSA. MRSA (USA200) was 
grown on TSA containing 1× , 2× , 4× , or 8× MIC of 3a up to 96 h at 37 °C (Figs 3 and S2). No colonies were 
observed on agar plates that contained more than 2× MIC of 3a after 24 h. MK-4 (100 μ g/mL) supplemented agar 
plate containing 8 μ g/mL of 3a showed wild-type colonies, indicating that the inhibitory activity was hampered 
by MK-4. However, no growth of SCV was observed even after incubation of TSA with 4–16 μ g/mL up to 96 h, 
suggesting 3a did not induce SCV. MRSA (USA200) was also grown on TSA containing 7c and rifampin (positive 
control). At 72 h, rifampin showed growth of SCV and confirming that 7c did not induce SCV (Fig. 3C).
Antimicrobial activity against MRSA biofilms. We next investigated if inhibitor 3a exhibits inhibitory 
activity against MRSA biofilms. Biofilms by Gram-positive bacteria are known to be more resistant to many 
antibiotics and the required concentration to eradicate biofilm is much higher than MIC27. Minocycline, a tet-
racycline antibiotic used for skin infection, was used as a control for biofilm eradication. It showed significant 
decrease in MRSA biofilm growth at concentrations of 0.5 and 0.03 mg/mL compared to the positive control 
(Fig. 4). Concurrently, Compound 3a showed 104, 106 and 107 fold decrease in MRSA growth from the treated 
biofilm at 0.03, 0.5 and 1 mg/mL, respectively. Thereby 3a was determined to be effective in reducing biofilm 
growth.
Growth Inhibition of extracellular MRSA (USA700) in human macrophages by inhibitor. We 
next investigated the bactericidal activities of inhibitors in human macrophages incubated with MRSA. 
Figure 2. Synthesis of Long chain MenA inhibitors. 
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Staphylococcus aureus isolates, MIC (ug/mL)
MSSA EF1 PA2 MA3 Mab4# R USA100 USA200 USA300 USA400 USA500 USA700 USA800
1 — — 16 16 — 16 — 32 8 128 — —
2 — — 16 16 — 16 — 16 16 > 64 — —
3a 4 2 4 4 4 4 6 4 1 > 64 2 6
3b 6 2 6 4 8 8 6 4 0.5 > 64 4 12
3c 6 2 4 4 6 4 6 4 1 > 64 4 12
3d — > 128 — 64 128 32 — 32 — — — —
3e — — — — — > 128 — — > 128 — — —
3f > 128 — — — — > 128 — — — — — —
3g — — — > 128 — > 128 — > 128 — > 128 — —
3h — — — > 128 — > 128 — > 128 — > 128 — —
3i — — — — — > 128 — — — — — —
4a — 128 — — — 128 — — — — — —
4b — — — — — 128 — — — > 128 — —
4c 8 — 8 8 16 16 16 16 — > 64 8
5a 16 4 4 8 — 4 — — 2 — — —
5b > 128 16 32 64 — 64 — — 16 — — —
5c 32 8 32 16 — 32 — — 8 — — —
5d 8 — — 4 — 16 — — — — — —
6a — 8 — 8 — 16 64 16 4 — — —
6b 6 4 6 6 12 16 12 4 2 > 128 2 —
6c > 128 — — > 128 > 128 > 128 > 128 > 128 — — — —
6d — — > 128 > 128 — 64 — 64 16 — — —
6e — 128 > 128 — — 128 — — — — — —
7a — > 128 — — — 128 — — — — — —
7b — — — — — > 128 — — — — — —
7c 3 2 3 1 8 2 4 2 1 > 128 3 6
7d — — — — — > 128 — — — — — —
Linezolid — 0.5 1 1 1 0.5 1 0.5 1 > 32 1 — —
Minomycin — — — — 0.5 < 0.06 — — — 16 — — —
Table 1.  Minimum inhibitory concentration against MRSA strains and other bacteria. 1EF: Enterococcus 
faecalis. 2PA: Pseudomonas aeruginosa. 3MA: Mycobacterium avium. 4Mab: Mycobacterium abscessus, MSSA: 
Methicillin susceptible Staphylococcus aureus, (− ): not determined.
www.nature.com/scientificreports/
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Figure 3. Menaquinone rescue (A) and colony morphology (B). (A) MRSA (USA 700 for 3a, USA 200 for 
3c) was treated with various concentrations of menaquinone (MK-4) in the presence of inhibitor. (B) MRSA 
(USA 200) was incubated on TSA containing various concentrations of 3a (0, 2, 4, 8, 16 μ g/mL and 8 μ g/mL + 
100 μ g/mL MK4) up to 96 h. (C) MRSA (USA 200) was incubated on TSA containing 7c and rifampin (positive 
control) up to 72 h.
Figure 4. Antibacterial activity against MRSA biofilm. MRSA (USA700) biofilms were treated with 3a or 
minocycline for 24 h and serially diluted and plated on TSA plates to determine CFU. Data represents the 
mean ± SEM of triplicate (n = 3). M: minocycline, Statistical differences were determined using Student’s t test: 
*p < 0.001 compared to (+ ) positive control.
www.nature.com/scientificreports/
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Monocyte-derived macrophages were obtained by incubating monocytes in the presence of MCSF in DMEM 
media containing 10% human serum. Adherent MDMs were incubated with MRSA (1 × 106 CFU/mL) and 
treated with inhibitors at concentrations of MIC and MIC/4 for 24 h. Extracellular MRSA surviving in media was 
determined by counting colonies. As seen in control experiments in Fig. 5, a 3 fold decrease of extracellular anti-
bacterial activity by MDMs was observed in culture media, indicating that MRSA was phagocytized and killed by 
MDMs. Our inhibitors were then tested in the presence or absence of MDMs. Antibacterial activities of inhibitors 
(3a, 6b, 7c) tested were increased by 6–12 fold compared to activities without MDMs and by 1.5 – 3-fold com-
pared to activities with MDMs. This result suggests that these inhibitors prevented extracellular bacterial growth 
at their MIC and MIC/4, but use of a concentration greater than the MIC is required for complete bactericidal 
activity. However, we did not observe concentration-dependent antibacterial activities when MDMs were treated 
with MRSA and inhibitors at different concentrations.
Figure 5. Macrophage-mediated inhibition of MRSA growth with inhibitors. Human monocytes were 
differentiated into macrophages (MDM) in the presence of MCSF. MDMs were incubated with MRSA (USA 
700) in the presence of inhibitor for 24 h at 37 °C. Media were serially diluted and plated on TSA to determine 
CFU. (− ): No MDM and No inhibitor, (+ ): No inhibitor. Data represents the mean ± SEM of triplicate (n = 3). 
Statistical differences were determined using Student’s t test: *p < 0.002, **p < 0.01 compared to (+ ) positive 
control.
Figure 6. TNF-α, IL-6 and IL-1β released from macrophages treated with long-chain inhibitors. THP-1 
macrophages were treated with 3a, 6b or 7c at concentrations equal to their MICs for 24 h at 37 °C. Culture 
supernatants were analyzed for cytokines. Data represents the mean ± SEM of triplicate samples (n = 3). Blank: 
No inhibitor was added. DMSO (< 0.05%), *out of range below the detection limit.
www.nature.com/scientificreports/
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Cytokine secretion by THP-1 macrophages treated with MenA inhibitors. Since MenA inhibitors 
enhanced the bactericidal activity of macrophages, we next examined whether macrophages treated with inhibi-
tors display an altered cytokine profile. The cytokines released from THP-1 macrophages were assessed from cul-
ture supernatants using a Luminex system. Among 10 cytokines analyzed, IL-8 was most abundant in ~25 ng/ml 
(Figure S2) but there was no significant difference in IL-8 expression in the presence or absence of inhibitors. 
Interestingly, we found that amounts of TNF-α and IL-6 released from THP-1 macrophages were decreased in 
the presence of inhibitors 3a, 6b and 7c whereas these inhibitors stimulated the release of IL-1β at concentrations 
equal to their MICs (Fig. 6). These intriguing results suggest that this class of small molecules, in addition to anti-
biotic activity, possesses potential to be developed as TNF-α and IL-6 suppressors for use as immunomodulatory 
therapy for the treatment of inflammatory diseases. In addition, IL-1β was also regulated by the same MenA 
inhibitors.
The MenA inhibitors are composed of three main groups: naphthol, carbon chain linker, and amine tail 
group. We explored this class of inhibitor by modifying these three main backbone structures to find a more 
potent lead structure against S. aureus. We found that 3a-c and 5a have potent activity against MRSA strains, 
MSSA and other bacteria with MIC values ranging 1–16 μ g/mL. As expected, all compounds showed no activity 
against Gram-negative P. aeruginosa. Interestingly, 7c showed very low MIC values against MK utilizing bacteria 
(Table 1), suggesting it is a potential lead compound for future optimization. MK rescue experiment confirmed 
the involvement of the MK biosynthetic pathway in reducing MRSA growth. MRSA strains treated with 3a or 7c 
were rescued by MK4, supporting disruption of electron transfer chain by MenA inhibitor. IC50 analysis also con-
firmed that MenA is the target for compounds. 3a was found to inhibit MRSA biofilm growth, which is defined 
as a sessile microbial community. S. aureus biofilms colonize medical implants and host tissue and contribute to 
the persistence of chronic infections. The cells are protected in an extracellular polymeric matrix in which their 
physiologies are altered with respect to gene expression and protein production. Thus, biofilm formation reduces 
susceptibility to antimicrobials and requires use of larger quantity of antimicrobials. As expected, minocycline 
as a reference did not completely inhibit MRSA (USA 700) biofilm at 8300 × MIC (broth MIC < 0.06 μ g/mL, 
Table 1), showing 106-fold reduction compared to the positive control. Likewise, treatment of MRSA biofilm 
with 3a (250 × MIC) inhibited the MRSA growth by 105 fold. The results suggest that MenA inhibitor 3a is highly 
effective in preventing MRSA growth.
Development of antibiotics that are active against both extracellular and intracellular pathogens is important 
to eradicate infectious bacteria. MenA inhibitors in the presence of macrophages showed promising activities 
against extracellular MRSA. We observed macrophage stimulation by MenA inhibitors alters the cytokine-release 
profile, causing a reduction of TNF-α and IL-6, and an increase of IL-1β . These three cytokines play a vital role in 
immune defense by responding to pathogens and inflammatory states. They have also been implicated as novel 
immunomodulatory therapeutic targets.
The pro- and anti-inflammatory IL-6 participates in the host immune defense. IL-6 binding to either form 
of its receptors (transmembrane and soluble IL-6 receptors) triggers biological signal transductions, affecting 
various cell populations28. However, dysregulation of IL-6 production is a major causative factor of autoimmune 
and chronic inflammatory diseases. There are various drugs that block IL-6 signaling pathways by targeting IL-6, 
IL-6 receptors or gp130 in development stage or market. For example, monoclonal antibody (tocilizumab) to 
IL-6R has been approved and used for treatment of rheumatoid arthritis, indicating that IL-6 blockade is a novel 
strategy for inflammatory diseases. Since macrophages are one of major sources of IL-6, reducing or blocking IL-6 
release from macrophages by an anti-IL-6 reagent is an alternative strategy in development of therapeutic agent. 
As shown in Fig. 6, it is observed that treatment of THP-1 macrophages with MenA inhibitors (3a, 6b, or 7c) 
significantly reduced IL-6 release, providing a rational strategy for the development of immunomodulatory agent 
and prompting us to investigate mechanism of action of MenA inhibitor that affects IL-6 release of macrophage.
Several monoclonal antibody drugs such as infliximab (Remicade), etanercept (Enbrel), adalimumab 
(Humira), certolizumab pegol (Cimzia) have been developed against tumor necrosis factor (TNF-α ) overproduc-
tion to treat inflammatory and autoimmune diseases including rheumatoid arthritis, psoriatic arthritis, ankylosing 
spondylitis and Crohn’s disease. It is also suggested that a combination of TNF inhibitors and antibiotics might 
be beneficial for treatment of S. aureus sepsis29. TNF-α is released by monocytes, lymphocytes and macrophages, 
and facilitates macrophage apoptosis in response to M.tb30–32. TNF-α also recruits other immune cells to sites of 
inflammation. During immune response to pathogens or stimuli, macrophages synthesize and secrete TNF to the 
extracellular space via a series of secretion pathways. Many trafficking proteins are involved to deliver TNF outside 
the plasma membrane. Our MenA inhibitor potentially inhibited TNF release from THP-1 macrophages by either 
inhibiting one of trafficking proteins involved in secretion pathways, or binding to a membrane receptor that 
blocks activation of macrophages during the immune response. Earlier, it was reported that adenosine as agonist 
reduces TNF-α release from macrophage by activating the cAMP-elevating A(2 A) adenosine receptor (AR) sub-
type33,34. However, further study will be conducted to identify the anti-inflammatory role of these MenA inhibitors.
Unlike TNF-α and IL-6, we observed an increase in IL-1β release from THP-1 macrophages by stimulation 
by MenA inhibitors. Pro-inflammatory cytokine IL-1β is important in defending infection, but dysregulation 
of IL-1β is responsible for chronic inflammatory diseases and acute tissue injuries35. These results indicate that 
stimuli-mediated secretion of cytokines is more complicated. It is challenging to develop selective stimulating 
agents that block the release of cytokines of interest.
A series of long-chain compounds were developed to inhibit growth of MRSA and other gram-positive bacteria 
that utilize menaquinone under aerobic conditions. MenA inhibitors displayed a promising extracellular bactericidal 
activity against growth of MRSA and its biofilm. More importantly, naphthalene-based MenA inhibitors showed 
potential as inhibitors of extracellular bacterial growth and as immunomodulatory agents to reduce the release of IL-6 
and TNF-α from macrophages. These MenA inhibitors could be used to reduce macrophage cytokine release and it 
would provide insight in the development of pharmaceuticals for MRSA septic shock and other inflammatory diseases.
www.nature.com/scientificreports/
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Methods
Materials. All chemicals were purchased from Aldrich (St. Louis, MO, USA) and Across (Geel, Belgium). 
Microbial species are purchased from ATCC (Manassas, VA, USA). NMR spectroscopies were recorded on a 
Varian Unity/Inova-500 NB (500 MHz, Varian Medical Systems Inc. Palo Alto, CA, USA). Chemical shifts are 
reported in parts per million (ppm) downfield from TMS. Molecular weight is determined using MALDI TOF/
TOF (Applied Biosystems, CA, USA).
Minimum inhibitory concentration (MIC) against S. aureus. 96-well plates were seeded with 5 × 105 
CFU/mL in a volume of 100 μ L of tryptic soy broth (TSB) per well for Staphylococcus aureus assays. Compounds were 
dissolved in DMSO and serially diluted as 1:2 dilutions to give the final concentration ranging from 0.25 to 128 μ g/mL 
per well. The final concentration of DMSO in the assay plates did not exceed 2%. Plates were incubated at 37 °C for 
18–20 hours and MIC was determined by reading OD625. For M.avium and M.abscessus, 7H9 broth media was used 
for determination of MICs. The final concentration was 5 × 105 CFU/mL in each well. The plate was incubated at 
37 °C for 7–8 days and MICs were determined using a Tecan microplate reader (OD625) and resazurin reduction assay.
Menaquinone rescue experiments with MRSA. Resazurin reduction assay was performed in 96-well 
plate. MRSA was cultured in TSB until OD625 reached 0.4~0.5 and diluted and plated in 96-well plate. MRSA (5 × 105 
CFU/mL/well) was treated with menaquinone (MK4, 0, 1, 5, 50, 500 μ g/mL) in the presence of 0.5~128 μ g/mL 
of inhibitor. The plate was incubated overnight at 37 °C followed by 20 μ L of resazurin (0.15 mg/mL) was added to 
each well. The plate was incubated for 2–4 h and fluorescence was measured at 560 nm excitation/590 nm emission.
Cytotoxicity Assay. To determine cytotoxicity of the inhibitors, THP-1 cells were differentiated into mac-
rophages by PMA (7.5 ng/mL) for 24 h. THP-1 macrophages (5 × 105/well) were treated with inhibitors in 48-well 
plates for 24 h at 37 °C in 5% carbon dioxide. Cells were washed with PBS buffer three times and serum-free cul-
ture medium was added to each well. Cytotoxicity was assessed using resazurin assay.
S. aureus biofilm assay. Biofilm assays were performed using a method previously described with modi-
fication36. A 96 well plate was precoated with 20% human plasma (Sigma) in 0.05 M carbonate buffer, pH 9.6 at 
4 °C for 24 h. MRSA was cultured overnight in TSB containing 3% NaCl and 0.5% glucose. The overnight culture 
was diluted with TSB/NaCl/Glucose media until OD600 reached 0.05. After carefully removing the liquid from the 
96 well plate, 200 μ L of MRSA dilution was added to each well in triplicate. The plate was incubated at 37 °C for 
24 h and carefully washed with PBS twice. MH broth (200 μ L) containing a compound was added to each well in 
triplicate and incubated at 37 °C for 24 h. After washing with PBS twice, the biofilm was scraped in 100 μ L of PBS 
and serially diluted and plated on TSA to determine CFU.
Colony morphology. MRSA was streaked and then incubated on tryptic soy agar (TSA) containing 0, 2, 4, 
8 or 16 μ g/mL of inhibitor 3a or 4 μg/mL of 7C or 0.025 μg/mL of rifampin at 37 °C for 96 h. MK-4 (100 μ g/mL) 
was supplemented in TSA containing 8 μ g/mL of 3a for the rescue experiment.
MenA inhibitor activity against extracellular S. aureus in the presence of human MDMs. 
Human monocyte-derived macrophages (MDM) were cultured at a concentration of 1 × 106 cells/mL/well in a 
24 well plate37. MRSA (USA 700) was cultured in TSB (10 mL) until OD625 reached 0.4~0.5 and then centrifuged 
at 14,000 rpm for 10 min. The pellets were resuspended in 10 mL of DMEM supplemented with 10% human serum 
(no antibiotics). The bacteria medium was diluted with DMEM containing an inhibitor to obtain 1 × 106 CFU 
/mL and added to human MDMs (MOI = 1) in a 24-well plate. After 24 hour infection at 37 °C, the supernatants 
were serially diluted for CFU determination (TSA plates).
Quantitation of cytokines. THP-1 cells were differentiated into macrophages by treatment with PMA 
(7.5 ng/mL). Levels of the human cytokines (GM-CSF, IFN-γ , IL-1β , IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, TNF-α ) 
released from THP-1 macrophages were determined using a multiplex kit from Life Technologies according to the 
manufacturer’s instructions. In brief, the 96 well filter plate was pre-wetted, and then 25 μ L of the diluted bead sus-
pension was added to each well and washed twice. 100 μ L of samples and standards were added to each well. The 
plate was incubated at room temperature for 2 h on a shaker. Following washing, biotinylated detection antibody 
was added and incubated for 1 h. After washing, streptavidin-RPE was added to each well and incubated for 0.5 h. 
The plate was again washed, resuspended in 100 μ L of the washing buffer, and read on the Luminex xMAP™ sys-
tem (Bio-Rad, AtheNA multi-Lyte™ , USA). All samples were run in triplicate and standards were run in duplicate.
Statistical analysis. Statistical analysis was performed using Student’s t-test. Data are represented as 
mean ± SEM. Data are significant at p < 0.05.
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